LENSAR (LNSR)
NASDAQ:LNSR
LNSR Stock Chart & Stats
$11.61
-$0.54(-6.29%)
At close: 4:00 PM EST
$11.61
-$0.54(-6.29%)
Day’s Range― - ―
52-Week Range$5.35 - $14.31
Previous CloseN/A
Volume40.10K
Average Volume (3M)58.95K
Market Cap
$73.30M
Enterprise Value$62.14M
Total Cash (Recent Filing)$17.98M
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding12,095,631
10 Day Avg. Volume51,870
30 Day Avg. Volume58,950
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)-5.34
Price to Sales (P/S)2.38
P/FCF Ratio-9.32
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.06
Enterprise Value/Gross Profit2.29
Enterprise Value/Ebitda-3.10
Forecast
1Y Price Target
$8.50Price Target Upside-26.79% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$85.20M
Bulls Say, Bears Say
Bulls Say
Install Base ExpansionContinued placements of the ALLY femtosecond system could expand Lensar's global install base and increase its share of cataract procedures, supporting revenue acceleration.
Recurring Revenue And Procedure GrowthRising procedure volumes and recurring revenue from consumables and service agreements may provide a stable foundation for Lensar to re-accelerate growth as clinical adoption widens.
Valuation And Potential Strategic InterestA valuation below ophthalmic peers combined with validation from a terminated acquisition could attract interest from larger competitors and create upside if market share gains persist.
Bears Say
Distributor Disruptions From Acquisition TerminationTermination of the acquisition disrupted international distributor relationships and required forecast adjustments, creating near-term sales headwinds.
Increased Competition From Larger Device MakersPlanned femtosecond and cataract systems from larger medical device companies could intensify competition and erode Lensar's market share gains.
Regulatory Review Impact On Sales MomentumExtended regulatory review of the proposed acquisition slowed sales momentum and softened revenue growth, introducing execution risk that could pressure results.
LENSAR News
LNSR FAQ
What was LENSAR’s price range in the past 12 months?
LENSAR lowest stock price was $5.35 and its highest was $14.31 in the past 12 months.
What is LENSAR’s market cap?
LENSAR’s market cap is $73.30M.
When is LENSAR’s upcoming earnings report date?
LENSAR’s upcoming earnings report date is May 07, 2026 which is in 31 days.
How were LENSAR’s earnings last quarter?
LENSAR released its earnings results on Mar 31, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of $0.185 by -$0.305.
Is LENSAR overvalued?
According to Wall Street analysts LENSAR’s price is currently Overvalued.
Does LENSAR pay dividends?
LENSAR does not currently pay dividends.
What is LENSAR’s EPS estimate?
LENSAR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LENSAR have?
LENSAR has 12,095,631 shares outstanding.
What happened to LENSAR’s price movement after its last earnings report?
LENSAR reported an EPS of -$0.12 in its last earnings report, missing expectations of $0.185. Following the earnings report the stock price went up 1.533%.
Which hedge fund is a major shareholder of LENSAR?
Currently, no hedge funds are holding shares in LNSR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENSAR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (-26.79% Downside)
$8.50 (-26.79% Downside)
Blogger Sentiment
Bullish
LNSR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 78.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.49%
12-Months-Change
Fundamentals
Return on Equity
197.15%
Trailing 12-Months
Asset Growth
7.74%
Trailing 12-Months
Company Description
LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
LNSR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational picture despite material near-term disruptions. Key strengths include strong recurring revenue growth (+15% YoY), robust procedure volume growth (+22% FY), rapid installed-base expansion (+48% ALLY YoY), positive adjusted EBITDA, and recovery of a $10M deposit plus concessions on acquisition liabilities. Primary challenges stem from the terminated acquisition and consequent distributor/customer uncertainty that depressed international system sales, elevated SG&A and merger-related expenses, and caused transient margin pressure. Management expects a multi-quarter re-acceleration as distributors reengage and commercial activities ramp, positioning the company to return to historical operating cadence.View all LNSR earnings summariesLNSR Stock 12 Month Forecast
Average Price Target
$8.50
▼(-26.79% Downside)
Technical Analysis
Ownership Overview
40.62% Insiders
8.21% Mutual Funds
21.00% Other Institutional Investors
23.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---